Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms

Blood

Volumn 121, Issue 14, 2013, Pages 2725-2733

  Kennedy, James A ^a   Atenafu, Eshetu G ^b   Messner, Hans A ^b   Craddock, Kenneth J ^a   Brandwein, Joseph M ^b   Lipton, Jeffrey H ^b   Minden, Mark D ^b   Schimmer, Aaron D ^b   Schuh, Andre C ^b   Yee, Karen W ^b   Gupta, Vikas ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMSACRINE; AZACITIDINE; CYTARABINE; DAUNORUBICIN; DECITABINE; ETOPOSIDE; HYDROXYUREA; MITOXANTRONE; RETINOIC ACID; VORINOSTAT; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC ANTIMETABOLITE; DRUG DERIVATIVE;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL OUTCOME; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA; LEUKEMIA REMISSION; LEUKEMIC TRANSFORMATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELOPROLIFERATIVE NEOPLASM; OVERALL SURVIVAL; PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; SPLEEN SIZE; TREATMENT RESPONSE; ADOLESCENT; CELL TRANSFORMATION; GENETICS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; REGISTER; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL TRANSFORMATION, NEOPLASTIC; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; REGISTRIES; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

MLCS; MLOWN;

EID: 84878225843     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-464248     Document Type: Article

References (20)

1. Mesa RA, Li C-Y, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood. 2005;105(3):973-977.
2. Tam CS, Nussenzveig RM, Popat U, et al; The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008;112(5):1628-1637.
3. Thepot S, Itzykson R, Seegers V, et al; Groupe Francophone des Myelodysplasies (GFM). Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2010;116(19): 3735-3742.
4. Noor SJ, Tan W, Wilding GE, et al. Myeloid blastic transformation of myeloproliferative neoplasms: a review of 112 cases. Leuk Res. 2011;35(5): 608-613.
5. Kundranda MN, Tibes R, Mesa RA. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep. 2012; 7(1):78-86.
6. Jurado M, Deeg H, Gooley T, et al. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol. 2001;112(2): 392-396.
7. Ciurea SO, de Lima M, Giralt S, et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant. 2010;16(4):555-559.
8. Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res. 2010;34(9):1246-1249.
9. Cherington C, Slack JL, Leis J, et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res. 2012;36(9): 1147-1151.
10. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
11. Barosi G, Mesa RA, Thiele J, et al; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and postessential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438.
12. Grimwade D, Hills RK, Moorman AV, et al; National Cancer Research Institute Adult Leukaemia Working Group. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-365.
13. Breems DA, Van Putten WLJ, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29): 4791-4797.
14. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367-369.
15. Gupta V, Daly A, Lipton JH, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant. 2005;11(10): 764-772.
16. Batlle M, Fernández-Avilés F, Ribera JM, et al. Acute promyelocytic leukemia in a patient with idiopathic myelofibrosis. Leukemia. 1999;13(3): 492-494.
17. Mollee PN, Taylor KM, Williams B, et al. Long-term molecular remission in promyelocytic transformation of myeloproliferative disease. Leukemia. 1999;13(4):648-650.
18. Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the societe francaise de greffe de moelle et de therapie-cellulaire and the groupe-francophone des myelodysplasies. J Clin Oncol. 2012;30(36): 4533-4540.
19. Brandwein JM, Gupta V, Schuh AC, et al. Predictors of response to reinduction chemotherapy for patients with acute myeloid leukemia who do not achieve complete remission with frontline induction chemotherapy. Am J Hematol. 2008;83(1):54-58.
20. Mascarenhas J, Heaney ML, Najfeld V, et al; Post-myeloproliferative neoplasm acute myeloid leukemia consortium. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012;36(12):1500-1504.